Structure-based discovery of anti-rotaviral agents

轮状病毒在世界范围内造成重大生命损失，特别是在5岁以下的儿童中。 每年有60多万5岁以下儿童死于轮状病毒感染。 澳大利亚每年因轮状病毒感染住院的病例超过10，000例。该项目的目的是，使用基于结构的药物设计技术，开发轮状病毒蛋白的抑制剂，这是其生命周期中必不可少的。 这些抑制剂可能会导致开发有用的药物来治疗轮状病毒感染，并可能减少这种致命病毒造成的重大生命损失。

Rotavirus causes, particularly in children under 5 years of age, significant loss of life worldwide. Over 600,000 children under 5 years of age per annum die as a result of rotavirus infection. Australia records over 10,000 hospitalisations per annum due to rotavirus infection. This project aims, using structure-based drug design techniques, to develop inhibitors of a rotavirus protein that is essential in its lifecycle. These inhibitors may lead to the development of useful drugs to treat rotavirus infection and may reduce significant loss of life caused by this deadly virus.